• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Vidaza (azacitidine)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Vidaza (azacitidine)

  • Profile

Profile

Contact Information

Website: http://www.vidaza.com/

Currently Enrolling Trials

    Show More

    General Information

    Vidaza (azacitidine) is an anti-neoplastic pyrimidine nucleoside analog used to treat several subtypes of myelodysplastic syndrome, diseases caused by abnormalities in the blood-forming cells of the bone marrow that result in underproduction of healthy blood cells. The drug exerts a cytotoxic effect on rapidly dividing cells, including cancerous cells, and may help restore normal function to genes controlling proper cellular differentiation and proliferation.

    Vidaza is specifically indicated for the treatment of the following myelodysplastic syndrome subtypes:

    • Refractory anemia
    • Refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions)
    • Refractory anemia with excess blasts
    • Refractory anemia with excess blasts in transformation
    • Chronic myelomonocytic leukemia

     

    Mechanism of Action

    Azacitidine utilizes a dual mechanism of action, causing the hypomethylation of DNA and exerting direct cytotoxic in abnormal hematopoietic cells in the bone marrow. Hypomethylation may restore normal gene function to genes controlling cellular division and differentiation (the genes presumed to be abnormal or nonfunctional in myelodysplastic syndromes). Cytotoxic effects cause the death of rapidly dividing abnormal cells. Vidaza is not strongly active in non-proliferating cells, limiting toxicity to that resulting from affected tissues.

    Side Effects

    Adverse events associated with the use of Vidaza may include (but are not limited to) the following:

    • Thrombocytopenia
    • Neutropenia
    • Nausea
    • Vomiting
    • Anorexia
    • Arthalgia
    • Injection site erythema
    • Injection site pain

    Additionally, animal models have demostrated teratogenic potential in both men and women, and embryotoxicity during pregnancy.

    Dosing/Administration

    Vidaza is administered via subcutaneous injection, with a starting dosing regimen of 75 mg/m2 daily for seven days, every four weeks. The dose may be increased to 100 mg/m2 if the initial dose is insufficient and toxicity was manageable.

    Clinical Trial Results

    FDA approval of Vidaza was based on a randomized, open-label, controlled trial that enrolled 191 patients (172 evaluable) with any of the five subtypes of myelodysplastic syndrome noted above. Subjects were randomized to receive either subcutaneous Vidaza plus supportive care (n=99) or supportive care alone (n=92); subjects in the supportive care arm were free to cross over to the Vidaza arm if their symptoms worsened during the trial. Vidaza was administered via subcutaneous injection at 75 mg/m2 daily for seven days every four weeks; the dose was increased to 100 mg/m2 if no beneficial effect was seen after two treatment cycles. The drug was seen to produce a statistically significant response in 15.7 percent (n=14 of 89) of evaluable subjects in the Vidaza arm, and 12.8 percent (n=6 of 47) of the crossover group. Of the Vidaza-arm subjects exhibiting a response, five of the 14 showed a complete response and nine of the 14 showed a partial response. Additional studies yielded consistent results. Furthermore, an additional 24 percent of subjects who did not meet partial response criteria were considered "improved," and two-thirds were no longer transfusion dependent.

     

     

     

    Approval Date: 2004-05-01
    Company Name: Pharmion Corporation
    Back to Listings

    Upcoming Events

    • 24May

      Powering an Effective Oversight Strategy with Clinical and Operational Insights

    • 25May

      2022 WCG Avoca Quality & Innovation Summit: Own the Future

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing